Analyst firms · Leerink Partners · ABCL

Leerink Partners ABCL price target and rating history

AbCellera Biologics Inc. (ABCL) · Health Care

Leerink Partners rates AbCellera Biologics Inc. (ABCL) Market Perform with a $4 price target, as of its latest action on Nov 7, 2025. It has published 3 rating actions on ABCL since February 2022, including 0 upgrades and 1 downgrade. Across 5 firms with a ABCL price target in the last 12 months, the median target is $13.

Current rating
Market Perform
Price target
$4
Median target, all firms
$13
Actions on ABCL
3

Leerink Partners price target on ABCL

$20$12$42023202420252026
Leerink Partners price target on ABCL, each point a stated target, February 2022 to November 2025.

Every Leerink Partners rating on ABCL

How other firms rate ABCL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$19Nov 18, 2026
UBSBuy$18Oct 12, 2026
Goldman SachsNeutral$13Sep 24, 2026
The Benchmark CompanyBuy$11Jul 7, 2026
Cantor FitzgeraldOverweight$7May 5, 2026

Questions about Leerink Partners and ABCL

What is Leerink Partners's price target for ABCL?
Leerink Partners's latest stated price target for AbCellera Biologics Inc. (ABCL) is $4, from its action on Nov 7, 2025.
What is Leerink Partners's rating on ABCL?
Leerink Partners rates ABCL Market Perform, a neutral rating, as of Nov 7, 2025.
When did Leerink Partners last change its view on ABCL?
On Nov 7, 2025, Leerink Partners downgrades to Market Perform from Outperform, price target $4.
How does Leerink Partners's ABCL target compare with other analysts?
Across 5 firms with a ABCL price target in the last 12 months, the median target is $13.

More ABCL rating histories

All Leerink Partners ratingsABCL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.